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Background and aim: Serum calprotectin is elevated in patients with inﬂammatory bowel disease (IBD).
Whether it correlates other markers of disease activity is unknown. The aim of this study was to correlate
serum calprotectin with biochemical and histological measures of intestinal inﬂammation.
Materials and methods: TNBS colitis was induced in wistar rats, and serial blood samples were collected at
0, 3, and 12 days. Animals were subsequently sacriﬁced for pathological evaluation at day 12. Serum cal-
protectin and cytokines were measured by ELISA. Pathologic changes were classiﬁed at the macroscopic
and microscopic levels.
Results: TNBS colitis induced elevated serum calprotectin, TNF and IL-6 within 24 h. Levels of serum cal-
protectin remained elevated in parallel to persistence of loose stool and weight loss to day 12. Serum cal-
protectin levels correlated with serum levels of TNF-a and IL6 (p < 0.001), but not CRP. Animals with
liquid stool had signiﬁcantly higher levels of serum calprotectin than control animals. There was a cor-
relation between macroscopic colitis scores, and levels of serum calprotectin.
Conclusion: Serum calprotectin levels correlate with biochemical and histological markers of inﬂamma-
tion in TNBS colitis. This biomarker may have potential for diagnostic use in patients with IBD.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Inﬂammatory bowel disease (IBD) is characterized by mucosal
inﬂammation in the intestinal tract and this process is strongly
associated with an individual’s disease course and risk of complica-
tions [1,2]. Patients who obtain mucosal healing have been associ-
ated with lower relapse rates and lower complication rates within
the IBD population [2,3]. Colonoscopy with tissue biopsy is cur-
rently the gold-standard to investigate a patient’s level or extent
of mucosal inﬂammation, especially in measuring response to ther-
apy. However, colonoscopies cannot always be performed in a
timely manner, and colonoscopies are expensive, invasive, and re-
quire a pathologist for biopsy analyses [4]. Other methods such as
CT, MRI or capsule endoscopy also carry signiﬁcant costs, and are
associated with risks such as radiation exposure, reactions to con-
trast, or obstruction [5–9].
Serum biomarkers that correlate with intestinal inﬂammation
have been sought-after as a minimally invasive alternative to thesetests. C-reactive protein levels have been used as a marker of active
Crohn’s, and a return to a normal levels can indicate mucosal heal-
ing [10–12]. Although this test is widely used, studies have shown
that the level of this protein does not always parallel disease activ-
ity, as a number of other conditions can lead to elevated CRP levels
in patients with inactive IBD [13]. Use of CRP as threshold for entry
into clinical trials of therapies for IBD has not signiﬁcantly reduced
the placebo rates, suggesting elevated levels alone are not a sensi-
tive marker of intestinal inﬂammation [13,14].
Calprotectin is a marker of neutrophil activation that has been
reported to be elevated in the blood and feces of patients with ac-
tive IBD [15,16]. In particular, fecal calprotectin has been studied as
a potential biomarker for IBD due to its non-invasive nature and
low cost [17,18]. In contrast, little has been published regarding
levels of serum calprotectin in colitis, and whether they correlate
with other markers of inﬂammation. The optimal biomarker in
IBD would be performed at the time of the medical visit and clearly
reﬂect the expression of inﬂammatory markers and the state of the
bowel mucosa. There is increasing interest in such a biomarker in
IBD, particularly to identify patients with active inﬂammation, ver-
sus those with mucosal healing [19]. It is unknown whether serum
calprotectin also exhibits these properties.
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protectin could be used as a marker of intestinal inﬂammation,
both microscopic and macroscopic, in an animal model of colitis.
We also sought to compare serum calprotectin to other markers
of intestinal inﬂammation, such as CRP, TNF and IL-6.2. Materials and methods
Colitis was induced with TNBS in male Wistar rats weighing 240
to 280 g according to the model proposed by Morris et al. [20]. The
animals were allowed to adjust to the laboratory, given water and
food, and subjected to a 12-h sleep-wake cycle. Three days later,
the animals were subjected to TNBS-induced colitis (n = 5). The
control group was administered a saline solution and followed in
parallel (n = 5).2.1. Induction of experimental colitis
Colitis was induced after the animals were anesthetized with
ketamine (100 mg/mL and 0.3 mL/animal), and the animals in the
TNBS group were given 2,4,6-nitrobenzenesulfonic acid (Sigma)
via intracolonic instillation at a concentration of 25 mg TNBS
(0.6 mL) dissolved in 0.25 mL of 50% ethanol, which was injected
into the colon 8 cm from the anal margin using PE-50 tubing. Next,
the animals were placed on a 90-degree plank for approximately
20 min. The control group was administered a physiological saline
solution via the same method that was used for the TNBS group.Fig. 1. TNBS colitis leads to systemic evidence of inﬂammation in treated animals. (A) Per
and TNBS-treated (colored column) animals. ⁄p > 0.05 by two-sided t test. (B) Microscopy
Mean serum TNF (13 pg/ml) in saline-treated (squares) and TNBS-treated (triangles) ani
serum IL-6 (3.8 pg/ml) in saline-treated (squares) and TNBS-treated (triangles) animals2.2. Assessment of inﬂammatory markers
The inﬂammatory (TNF-a and IL-6) and activity (serum calpro-
tectin and C-reactive protein) markers were assessed 1 h after the
administration of TNBS or saline (day 0). The serum samples were
collected on day 3 and day 12, and the animals were sacriﬁced on
day 12.
To determine the serum concentrations of IL-6, TNF-a and cal-
protectin, speciﬁc ELISA kits were used. These included the IL-6 rat
ELISA kit from BD Pharmingen (sensitivity level, 3.8 pg/mL), the
TNF-a rat ELISA kit from BD Pharmingen (sensitivity, 13 pg/mL),
and the calprotectin ELISA kit from Immunodiagnosis SA (1009/
SA1009/Sa 1008 kit 6935; sensitivity, 0.25 ng/mL). The C-reactive
protein level was measured using an immunoturbidimetry method
and the ultra-sensitive C-reactive protein AU600 kit from Olympus
(sensitivity level, 0.53 to 18.08 mg/dL).2.3. Macroscopic and microscopic assessment
The animals were sacriﬁced on day 12 after the serum samples
had been collected. The colons were removed, opened, and stained
with Evans blue. Three different observers established the macro-
scopic score by using a magnifying glass, and these evaluations
are described in Fig. 1.
The most heavily damaged tissue sites were selected for stain-
ing. These samples were ﬁxed in 10% formalin and then subjected
to parafﬁn and hematoxylin-eosin staining. Two different patholo-
gists examined and scored the samples, as described in Fig. 2.cent change in mean body weight between day 0 and day 12 in saline (clear column)
image on H&E-stained section of rat intestine from TNBS-treated animal (40). (C)
mals at various time-points after treatment. ⁄p > 0.05 by two-sided t test. (D) Mean
at various time-points after treatment. ⁄p > 0.05 by two-sided t test.
Fig. 2. Serum calprotectin levels correlate with biochemical markers of colitis. (A) Mean serum calprotectin (0.25 ng/ml) in saline-treated (squares) and TNBS-treated
(triangles) animals at various time-points after treatment. ⁄p > 0.05 by two-sided t test. (B) Correlation between serum calprotectin (x-axis) and serum TNF (Y-axis) in animals
treated with saline or TNBS. Straight line represents linear regression slope for correlation of x and y variables. (C) Correlation between serum calprotectin (x-axis) and serum
IL-6 (Y-axis) in animals treated with saline or TNBS. Straight line represents linear regression slope for correlation of x and y variables. (D) Correlation between serum
calprotectin (x-axis) and serum CRP (Y-axis) in animals treated with saline or TNBS. Straight line represents linear regression slope for correlation of x and y variables.
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The data presented are summarised in frequency tables or as
means, standard deviations, ranges, or proportions, as indicated.
The baseline data are expressed as the means ± standard devia-
tions. The follow-up measurements of the continuous variables
are summarised as absolute values and absolute and percent
changes, which are given with respect to the baseline. The dichot-
omous variables were summarised in frequency tables or as means
and proportions.
For the repeated measurements, an ANOVA was used to com-
pare the outcome levels of interest between the time-points, and
p-values of <0.05 were considered to be signiﬁcant. For this pur-
pose, Fisher’s test of least-squares differences was used when it
was allowed by the F-test. Student’s t-test was used for pairwise
comparisons with Bonferroni corrections. The data not normally
distributed were analysed using non-parametric tests. For these
tests, p-values of <0.05 were considered to be signiﬁcant. The
chi-squared test or Fisher’s exact test was used to analyse the cat-
egorical data. The data were analysed using JMP software (SAS,
Cary, NC).
2.5. Ethics committee
This study protocol (number 2444) was approved by the ethics
committee of the Federal University of São Paulo (UNIFESP) on June
17, 2009. Each of the research stages followed the Guide for the
Care and Use of Laboratory Animals from the Institute of Labora-
tory Animal Resources, Commission on Life Sciences, NationalResearch Council (National Academy Press, Washington, DC,
1996).
3. Results
Introduction of TNBS led to signiﬁcant weight loss (mean 10%
loss in body weight) and development of liquid bloody stools in
all exposed animals, whereas control (saline) animals remained
healthy and gained weight (mean 30% gain over 12 days)
(Fig. 1A). At the time of sacriﬁce on Day 12, all TNBS-treated ani-
mals have microscopic and macroscopic evidence of colitis
(Fig. 1B). In the serum compartment, levels of TNF and IL-6 were
signiﬁcantly higher in TNBS-treated than control animals 24 h after
induction of TNBS colitis, but declined by days 3 and 12 (Fig. 1C
and D).
In contrast, serum calprotectin levels were signiﬁcantly ele-
vated after TNBS, and remained elevated on day 3 and day 12, in
parallel to objective evidence of disease in the animals (Fig. 2A).
Levels were threefold higher (mean 21,786 ng/mL than those mea-
sured in saline-treated animals (mean 4032). A linear correlation
was observed between the serum levels of calprotectin and those
of TNF-a (r2 0.7, p < 0.001) and IL-6 (r2 0.79, p < 0.0001) in saline
and TNBS-treated animals on Day 3 (Fig. 2B and C). There was no
correlation between serum calprotectin and CRP (r2 0.1, p = 0.06)
(Fig. 2D).
When grouped according to clinical signs of colitis, animals
with liquid stool had signiﬁcantly higher serum calprotectin levels
than those with normal stool consistency (Fig. 3A). Similarly, ani-
mals with intestinal macroscopic damage scores >4 had higher
Fig. 3. Serum calprotectin reﬂects clinical and endoscopic markers of colitis. (A) Serum calprotectin levels grouped according to stool score on Day 3 (0 = normal, 1 = liquid) in
animals treated with saline or TNBS (horizontal line = mean). (B) Serum calprotectin levels in individual animals grouped according to stool score on Day 3 (0 = normal,
1 = liquid) in animals treated with saline or TNBS (horizontal line = mean). ROC curve for characteristics of serum calprotectin to identify macroscopic inﬂammation score > 2
in TNBS-treated animals.
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ine) or mild damage (scores 1–4) (Fig. 3B). When an ROC curve was
plotted for serum calprotectin for macroscopic damage (score >2),
the area under the curve value was 0.94, with a serum level of 9500
being the optimal cut-off value in TNBS colitis (Fig. 3).
4. Discussion
This study has demonstrated that TNBS-induced colitis pro-
vokes elevations in serum calprotectin that correlate closely to bio-
chemical and endoscopic measures of colitis. Unlike TNF and IL-6,
which declined after the acute phase, this marker remained ele-
vated with persistent inﬂammation in the intestinal tract.
Calprotectin is a Toll-like receptor-4 (TLR4) ligand expressed by
neutrophils, monocytes, and early differentiated macrophages [21].
These cell populations are all elevated in the peripheral blood of pa-
tients with ulcerative colitis (UC), secrete pro-inﬂammatory cyto-
kines, and correlate with levels of intestinal inﬂammation [22,23].
Serum levels of calprotectin are elevated in some inﬂammatory con-
ditions, and selective removal of peripheral blood activated granulo-
cytes and monocytes/macrophages leads to a decline in fecal
calprotectin levels in patients with UC [24,25]. Some studies have
demonstrated that calprotectin in the stool can be a good marker
to evaluate the activity of the disease as well as predict its severity
[25,26].This study has demonstrated that measuring calprotectin in
serum may provide a more practical means for measuring this bio-
marker in practice. Not only did it correlate with stool output, and
serum biochemistry, it also exhibited high correlation with endo-
scopic scores in this model. This is a key characteristic in future
markers for patients with IBD, where markers of mucosal healing
will be required [27]. Future studies in this model would require a
comparison between serum and fecal calprotectin levels to deter-
mine which correlates highly with intestinal inﬂammation.
In recent years, TNF-a, IL-1, and IL-6, have been attributed
increasingly important roles in the physiopathology of inﬂammatory
diseases [28]. It is believed that increased levels and excessive syn-
thesis of these mediators result in a loss of bowel homeostasis, which
leads to signiﬁcant disequilibrium and directly contributes to disease
development. The results of this study have conﬁrmed the participa-
tion of TNF-a and IL-6 in TNBS-induced inﬂammation, which has
been previously described [29]. However, we have demonstrated thatboth cytokines decline by day 12 in this model, despite on-going evi-
dence of histologic and endoscopic inﬂammation. This may explain
why neither have been adopted as markers of disease activity in pa-
tients with IBD, as many Crohn’s disease patients exhibit normal ser-
um levels of these mediators [30,31].
C-reactive protein (CRP) is also used in clinical practice as a mar-
ker of intestinal inﬂammation in IBD. However, no correlation was
found when comparing the serum calprotectin and C-reactive pro-
tein levels in our studies (Fig. 3). These ﬁndings conﬁrm what other
groups have found with respect to CRP and inﬂammation in patients
with ulcerative colitis [32]. This may have been due to the fact that
the C-reactive protein levels peak at the beginning of the disease
process and then decrease rapidly. Alternatively, this may have been
due to genetic polymorphism, which has been repeatedly described
in humans [33,34] the microscopic and macroscopic disease scores
were very closely related to the serum calprotectin levels, which
suggest that this protein reﬂects the state of the bowel mucosa. In
medical practice, a real-time assessment of disease activity during
a clinical visit has paramount importance for deciding which thera-
peutic strategy or diagnostic imaging technique to employ (e.g.,
colonoscopy). Our results indicate that the serum levels of calprotec-
tin could bemeasured during routine laboratory tests, as a marker of
underlying intestinal inﬂammation. This measurement has also been
shown to be related to the stages of inﬂammatory bowel disease,
based on the expression of the inﬂammatory markers IL-6 and
TNF- a and the state of the bowel mucosa. Further study in humans
with IBD would be required to conﬁrm this data.
5. Conclusion
Serum calprotectin levels exhibited a direct correlation with the
levels of the chemical mediators of inﬂammation but did not cor-
relate with the levels of C-reactive protein. Serum calprotectin lev-
els were also shown to have a direct relationship with the
macroscopic and microscopic disease scores.
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